ONWARD
ONWARD, formerly known as GTX Medical, today announced the first patient has been enrolled in a pivotal trial evaluating the Company’s ARC TherapyTM . The pivotal trial, known as Up-LIFT, will evaluate the safety and effectiveness of ARC Therapy in restoring hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology. The first patient was enrolled at the Shepherd Center in Atlanta, GA, USA.
“For individuals with impaired arm and hand function due to spinal cord injury, improved hand function directly translates into meaningful gains in terms of quality of life - being able to eat, dress or perform other day-to-day activities,” said Edelle Field-Fote, PT, PhD, FAPTA, FASIA, co-PI of the Up-LIFT trial and Director of Spinal Cord Injury Research and Professor of Rehabilitation Medicine at Emory University School of Medicine.
“The start of this trial marks a significant milestone in bringing non-invasive stimulation to people living with spinal cord injury, whose top priority is restoring hand and arm function,” said Chet Moritz, PhD, co-PI of the Up-LIFT trial and Associate Professor in the Departments of Electrical & Computer Engineering and Rehabilitation Medicine at the University of Washington in Seattle. ONWARD plans to enroll 65 subjects at up to 15 sites in the United States, Canada, UK, and Europe.
A study recently published by Chet Moritz and researchers at the University of Washington in Transactions on Neural Systems and Rehabilitation Engineering , a journal of the IEEE, the world’s largest technical professional organization for the advancement of technology, demonstrated ONWARD’s transcutaneous spinal cord stimulation leads to both rapid and sustained recovery of hand and arm function for people with both motor complete and incomplete cervical SCI. These findings further support the potential for non-invasive spinal cord stimulation technology in restoring hand and arm function in this population.
“The initiation of the Up-LIFT trial is an important first step toward delivering meaningful solutions to people living with the effects of spinal cord injury,” said Dave Marver, Chief Executive Officer of ONWARD. “We are deeply committed to our vision to use breakthrough science and pioneering technology to help the spinal cord injury community.”
An arc occurs when an electrical impulse bridges the gap between two conductors. ARC Therapy is designed to re-establish severed connections between spared neural networks and the brain by means of specific, targeted spinal cord stimulation.
To learn more about ONWARD’s ARC therapy technology and mission to restore movement, independence and health in people with spinal cord injury, please visit the newly launched ONWD.com .
About ONWARD
ONWARD (@onwdempowered ), formerly known as GTX Medical, is a medical technology company focused on the development and commercialization of innovative therapies to facilitate functional recovery of people with spinal cord injury. Driven by a mission to restore movement, independence, and health in people with spinal cord injury, ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM ) or external (ARCEX ) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 19:00:00 CEST | Press release
PIF joins inaugural FIFA Club World Cup™ ahead of kick-off on June 14 in Miami The partnership expands PIF’s global footprint in sports and reflects a shared commitment with FIFA to fuel growth and engagement in football FIFA Club World Cup 2025™ will make history, redefining club football and bringing 32 of the world’s best clubs together for the first time PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football c
Orange Logic Appoints Ben Colenso as Managing Director, EMEA5.6.2025 18:41:00 CEST | Press release
Strategic hire underscores company’s growth and commitment to the region Orange Logic, the leader in digital asset management and content orchestration, today announced the appointment of Ben Colenso as Managing Director for EMEA. Based in the UK, Colenso will spearhead Orange Logic’s regional strategy, customer enablement, and market expansion efforts, as the company accelerates its global footprint. Colenso brings 20 years of experience in technology and media production, having most recently led the technology strategy for Hogarth, WPP’s content experience company. Known for solving complex problems for some of the world’s most iconic brands with his customer-centric approach, Colenso will play a critical role in strengthening Orange Logic’s presence and partnerships across EMEA which span customers such as ITV, Pearson, GSK, Ubisoft and Tourism Ireland amongst others. “Ben’s appointment reflects our deep commitment to EMEA, where we continue to see strong momentum and increasing de
Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20405.6.2025 17:22:00 CEST | Press release
All SAP software licensees can now easily extend the useful life and maximize the full value of their current, proven and stable mission-critical systems and enjoy total maintenance savings of up to 90% without the requirement of a costly and risky migration to S/4HANA on RISE Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has extended full support coverage for all SAP ECC 6.0 and S/4HANA releases through 2040, without any need to complete a migration to S/4HANA on RISE as required by SAP for clients who want to remain on SAP’s Annual Support and receive full support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605581964/en/ Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 2040 Rimini S
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform5.6.2025 16:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive global patent strategy and highlights the innovation and international recognition of the company’s proprietary technologies. RenMab™ mice are a core member of Biocytogen’s independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts.
Pink Bows Foundation Expands Showstop® Procedure Training and Certification Across Europe5.6.2025 16:00:00 CEST | Press release
Denmark’s Roskilde Festival hosts two days of Showstop Procedure training, 25 years after 9 tragic deaths Pink Bows Foundation (“organization” or “Pink Bows”) announced today another milestone - its global expansion - growing its impact with the successful delivery of two additional accredited Showstop® Procedure courses hosted by Denmark’s Roskilde Festival and attended by Paleo Festival and Engage Festival, among other event organizers and managers across Europe. Other sold-out training sessions took place in Dublin and Glasgow, with further courses to be announced for Fall 2025. “Never stop learning and improving. I believe that we have a good system for stopping a show at Roskilde Festival and RFX. We still hosted a course on Showstop procedure today on behalf of Pink Bows Foundation,” said Morton Therkilsden, Director of Safety, Roskilde Festival. Since its launch in Houston, Texas in March 2025, Pink Bows has trained 200 event professionals across the US, UK, Ireland and Denmark.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom